Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of “Buy” from Analysts

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have earned a consensus rating of “Buy” from the nine analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $34.00.

Several brokerages have recently weighed in on RCUS. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. HC Wainwright restated a “neutral” rating and issued a $20.00 price target on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Barclays lifted their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Friday, October 25th. Finally, Wells Fargo & Company assumed coverage on shares of Arcus Biosciences in a report on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 target price for the company.

Arcus Biosciences Stock Down 0.1 %

RCUS stock opened at $14.89 on Friday. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -4.73 and a beta of 0.88. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The business’s 50-day moving average is $16.08 and its two-hundred day moving average is $16.04. Arcus Biosciences has a fifty-two week low of $13.52 and a fifty-two week high of $20.31.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.06. The firm had revenue of $48.00 million for the quarter, compared to analysts’ expectations of $38.95 million. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The business’s quarterly revenue was up 50.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.94) EPS. As a group, analysts forecast that Arcus Biosciences will post -3.2 earnings per share for the current year.

Hedge Funds Weigh In On Arcus Biosciences

Institutional investors have recently bought and sold shares of the stock. Louisiana State Employees Retirement System boosted its position in shares of Arcus Biosciences by 2.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 27,500 shares of the company’s stock valued at $419,000 after acquiring an additional 700 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Arcus Biosciences by 2.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company’s stock valued at $471,000 after purchasing an additional 843 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Arcus Biosciences by 2.6% during the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock valued at $668,000 after purchasing an additional 1,117 shares during the last quarter. WINTON GROUP Ltd grew its stake in shares of Arcus Biosciences by 3.3% in the 2nd quarter. WINTON GROUP Ltd now owns 59,137 shares of the company’s stock worth $901,000 after buying an additional 1,872 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Arcus Biosciences by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 58,173 shares of the company’s stock worth $886,000 after buying an additional 1,951 shares during the last quarter. 92.89% of the stock is owned by hedge funds and other institutional investors.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.